FRONTLINE MEDICAL SCIENCES AND PHARMACEUTICAL JOURNAL (ISSN – 2752-6712)
VOLUME 03 ISSUE 06 Pages: 07-12
SJIF IMPACT FACTOR (2021: 5.14) (2022: 5.605) (2023: 6.659)
OCLC – 1272874727
Publisher: Frontline Journals



Journal Website: https://frontlinejournals.org/journals/index.php/fmspj

Research Article

VACCINE MANAGEMENT: A GLOBAL STANDARD REVIEW AND ANALYSIS OF VACCINE MANUFACTURING IN BANGLADESH

Submission Date: May 26, 2023, **Accepted Date:** May 31, 2023,
Published Date: June 05, 2023
Crossref doi: https://doi.org/10.37547/medical-fmspj-03-06-02

Amimul Islam
Department of Pharmacy, University of Science and Technology Chittagong (Ustc), Chattogram, Bangladesh

ABSTRACT

This article presents a comprehensive review and analysis of global standards in vaccine management, with a specific focus on the context of vaccine manufacturing in Bangladesh. By examining the current scenario of vaccine production in Bangladesh, this study aims to identify strengths, challenges, and potential areas for improvement in order to enhance the country's vaccine manufacturing capabilities. The analysis of global standards highlights the importance of quality control measures, supply chain management, storage and distribution practices, cold chain systems, and post-marketing surveillance. The findings from this study contribute to the understanding of vaccine management practices and provide insights for optimizing vaccine manufacturing in Bangladesh.

KEYWORDS

Vaccine management, global standards, vaccine manufacturing, Bangladesh, quality control, supply chain management, storage and distribution, cold chain systems, post-marketing surveillance, public health.

FRONTLINE MEDICAL SCIENCES AND PHARMACEUTICAL JOURNAL
(ISSN – 2752-6712)
VOLUME 03 ISSUE 06 Pages: 07-12
SJIF IMPACT FACTOR (2021: 5.14) (2022: 5.605) (2023: 6.659)
OCLC – 1272874727
Publisher: Frontline Journals

INTRODUCTION

Vaccination is a critical tool in public health, offering effective prevention against numerous infectious diseases. The efficient management of vaccines is essential to ensure their safety, efficacy, and accessibility. This article aims to provide a comprehensive review and analysis of global standards in vaccine management, with a specific focus on the context of vaccine manufacturing in Bangladesh. By examining the current scenario of vaccine production in Bangladesh, this study seeks to identify strengths, challenges, and potential areas for improvement in order to enhance the country's vaccine manufacturing capabilities.

Effective vaccine management involves a range of factors, including quality control measures, supply chain management, storage and distribution practices, cold chain systems, and post-marketing surveillance. Understanding the global standards in these areas and assessing their implementation in the context of Bangladesh will contribute to optimizing vaccine manufacturing and overall public health outcomes.

METHOD

To conduct this study, a systematic approach was followed to gather relevant information and insights on vaccine management. A comprehensive literature review was conducted to identify global standards and best practices in vaccine manufacturing and management. The review encompassed research articles, official guidelines, reports, and publications from reputable sources such as the World Health Organization (WHO), the Centers for Disease Control and Prevention (CDC), and other relevant international organizations.

Additionally, primary data was collected through interviews and consultations with key stakeholders in the field of vaccine manufacturing in Bangladesh. Experts from government agencies, vaccine manufacturers, regulatory bodies, and public health organizations were engaged to gain first-hand insights into the current state of vaccine production, challenges faced, and potential opportunities for improvement. These interviews and consultations provided valuable perspectives on

FRONTLINE MEDICAL SCIENCES AND PHARMACEUTICAL JOURNAL
(ISSN – 2752-6712)
VOLUME 03 ISSUE 06 Pages: 07-12
SJIF IMPACT FACTOR (2021: 5.14) (2022: 5.605) (2023: 6.659)
OCLC – 1272874727
Publisher: Frontline Journals

the strengths and weaknesses of vaccine management practices in Bangladesh.

The collected data from both the literature review and primary sources were analyzed using qualitative and quantitative methods. The analysis aimed to identify common themes, challenges, and potential strategies for enhancing vaccine manufacturing in Bangladesh based on the global standards and best practices identified in the literature.

Overall, the combination of a comprehensive literature review and primary data collection through interviews and consultations ensures a comprehensive and evidence-based analysis of vaccine management practices and their implementation in the context of Bangladesh. The findings from this study will provide valuable insights and recommendations for policymakers, vaccine manufacturers, and public health professionals to strengthen vaccine manufacturing capabilities and improve overall vaccine management in Bangladesh.

RESULTS

The analysis of global standards in vaccine management revealed several key elements crucial for efficient vaccine production. Stringent quality control measures emerged as a vital aspect of vaccine manufacturing, ensuring the safety and efficacy of vaccines. These measures include rigorous testing of raw materials, comprehensive quality assurance protocols throughout the production process, and adherence to Good Manufacturing Practices (GMP). Supply chain management also emerged as a critical factor, encompassing the procurement of raw materials, production scheduling, inventory management, and timely distribution of vaccines.

Standardized storage and distribution practices play a crucial role in maintaining the integrity of vaccines. This involves proper temperature control, monitoring, and maintenance of cold chain systems, as well as appropriate packaging and labeling. Cold chain systems are essential for preserving the potency of vaccines, especially those requiring specific temperature ranges for storage and transportation. Post-marketing surveillance, including monitoring of adverse events following immunization (AEFI), is another essential component to ensure ongoing safety and effectiveness evaluation of vaccines.

FRONTLINE MEDICAL SCIENCES AND PHARMACEUTICAL JOURNAL
(ISSN – 2752-6712)
VOLUME 03 ISSUE 06 Pages: 07-12
SJIF IMPACT FACTOR (2021: 5.14) (2022: 5.605) (2023: 6.659)
OCLC – 1272874727
Publisher: Frontline Journals

In the context of Bangladesh, the analysis highlighted several strengths in vaccine manufacturing. The country has made significant progress in developing indigenous vaccine production capabilities and has successfully introduced several vaccines into the national immunization program. Collaborations with international organizations and partnerships with global vaccine manufacturers have played a crucial role in technology transfer, capacity building, and knowledge sharing.

Discussion

Despite these strengths, several challenges were identified in vaccine manufacturing in Bangladesh. Limited manufacturing capacity, lack of infrastructure, and resource constraints were key issues affecting the scale and efficiency of production. Additionally, the dependence on imported raw materials and equipment posed challenges in terms of cost, availability, and quality control.

Furthermore, ensuring the quality and safety of vaccines throughout the supply chain, including distribution to remote areas, remains a significant challenge. Weaknesses in cold chain systems, inadequate training of healthcare professionals on vaccine management, and gaps in post-marketing surveillance were also identified as areas requiring attention.

Conclusion

This study provides a comprehensive review and analysis of global standards in vaccine management and the current state of vaccine manufacturing in Bangladesh. It highlights the importance of stringent quality control measures, supply chain management, standardized storage and distribution practices, cold chain systems, and post-marketing surveillance.

While Bangladesh has made commendable strides in vaccine manufacturing, several challenges and areas for improvement were identified. Addressing these challenges will require strategic investments in infrastructure, technology, and human resources, as well as strengthening collaborations with international partners. Efforts should focus on enhancing manufacturing capacity, improving cold chain systems, training healthcare professionals, and implementing robust quality control mechanisms.

FRONTLINE MEDICAL SCIENCES AND PHARMACEUTICAL JOURNAL
(ISSN – 2752-6712)
VOLUME 03 ISSUE 06 Pages: 07-12
SJIF IMPACT FACTOR (2021: 5.14) (2022: 5.605) (2023: 6.659)
OCLC – 1272874727
Publisher: Frontline Journals

By aligning with global standards and best practices, Bangladesh can enhance its vaccine manufacturing capabilities, ensuring the availability of safe and effective vaccines for its population. This will contribute to the overall public health outcomes, strengthening disease prevention and control efforts in the country.

REFERENCES

1. Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR, Elvin L, Ensor KM, Hackell J, Siber G, Malinoski F. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. The Pediatric infectious disease journal. 2000 Mar 1;19(3):187-95.
2. Graham JE, Borda-Rodriguez A, Huzair F, Zinck E. Capacity for a global vaccine safety system: the perspective of national regulatory authorities. Vaccine. 2012 Jul 13;30(33):4953-9.
3. Smith PJ, Battaglia MP, Huggins VJ, Hoaglin DC, Rodén AS, Khare M, Ezzati-Rice TM, Wright RA. Overview of the sampling design and statistical methods used in the National Immunization Survey22. American Journal of Preventive Medicine. 2001 May 1;20(4):17-24.
4. Habib MA, Alam MZ. Business analysis of pharmaceutical firms in Bangladesh: problems and prospects. Journal of Business and Technology (Dhaka). 2011;6(1):61-77.
5. World Health Organization. Global Vaccine Action Plan 2011-2020. Global Vaccine Action Plan 2011-2020.. 2013.
6. Marshall V, Baylor NW. Food and Drug Administration regulation and evaluation of vaccines. Pediatrics. 2011 Apr 18:peds-2010.
7. Zaffran M, Vandelaer J, Kristensen D, Melgaard B, Yadav P, Antwi- Agyei KO, Lasher H. The imperative for stronger vaccine supply and logistics systems. Vaccine. 2013 Apr 18;31:B73-80.
8. Levinson DR, General I. Vaccines for children program: vulnerabilities in vaccine management. Department of Health and Human Services: Office of Inspector General. 2012 Jun.
9. Nossal GJ. Vaccines and future global health needs. Philosophical Transactions of the Royal Society of London B:

FRONTLINE MEDICAL SCIENCES AND PHARMACEUTICAL JOURNAL (ISSN – 2752-6712)
VOLUME 03 ISSUE 06 Pages: 07-12
SJIF IMPACT FACTOR (2021: 5.14) (2022: 5.605) (2023: 6.659)
OCLC – 1272874727
Publisher: Frontline Journals

Biological Sciences. 2011 Oct 12;366(1579):2833-40.

10. Rappuoli R, Mandl CW, Black S, De Gregorio E. Vaccines for the twenty-first century society. Nature Reviews Immunology. 2011 Dec;11(12):865.